Company Overview
| Stock Name | Zhaoke Ophth-B |
|---|---|
| Stock Code | 06622 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 眼科製藥公司,致力於療法的研究、開發及商業化,擁有包含25種候選藥物的全面眼科藥物管線,涵蓋眼前節及眼後節多數主要眼科適應症,並建立先進眼藥製造設施及營銷團隊。 |
| Listing Date | 2021-04-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省廣州市南沙區珠江工業園美德三路1號 |
| Business Address (Hong Kong) | 香港沙田香港科學園3期12W座7樓716室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | zkoph.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 16.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 8,400 |
| Par Value | To be extracted |
| Offer Period | 2021-04-16 to 2021-04-21 |
| Global Offering Shares | 123,567,500 shares |
| HK Public Offer Shares (Initial) | 12,357,000 shares (10.0%) |
| Public Offer Lots (Initial) | 24,714lots (Pool A12,357lots,Pool B12,357lots) |
| International Placing Shares (Initial) | 111,210,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 535,155,500 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 20.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 2,075,934,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 8,400 |
| 1 lots | 500 | HK$ 8,400 |
| 2 lots | 1,000 | HK$ 16,800 |
| 2 lots | 1,000 | HK$ 16,800 |
| 3 lots | 1,500 | HK$ 25,200 |
| 4 lots | 2,000 | HK$ 33,600 |
| 5 lots | 2,500 | HK$ 42,000 |
| 5 lots | 2,500 | HK$ 42,000 |
| 6 lots | 3,000 | HK$ 50,400 |
| 6 lots | 3,000 | HK$ 50,400 |
| 7 lots | 3,500 | HK$ 58,800 |
| 8 lots | 4,000 | HK$ 67,200 |
| 9 lots | 4,500 | HK$ 75,600 |
| 10 lots | 5,000 | HK$ 84,000 |
| 12 lots | 6,000 | HK$ 100,800 |
| 12 lots | 6,000 | HK$ 100,800 |
| 14 lots | 7,000 | HK$ 117,600 |
| 14 lots | 7,000 | HK$ 117,600 |
| 16 lots | 8,000 | HK$ 134,400 |
| 18 lots | 9,000 | HK$ 151,200 |
| 20 lots | 10,000 | HK$ 168,000 |
| 30 lots | 15,000 | HK$ 252,000 |
| 30 lots | 15,000 | HK$ 252,000 |
| 40 lots | 20,000 | HK$ 336,000 |
| 50 lots | 25,000 | HK$ 420,000 |
| 50 lots | 25,000 | HK$ 420,000 |
| 60 lots | 30,000 | HK$ 504,000 |
| 60 lots | 30,000 | HK$ 504,000 |
| 70 lots | 35,000 | HK$ 588,000 |
| 70 lots | 35,000 | HK$ 588,000 |
| 80 lots | 40,000 | HK$ 672,000 |
| 80 lots | 40,000 | HK$ 672,000 |
| 90 lots | 45,000 | HK$ 756,000 |
| 100 lots | 50,000 | HK$ 840,000 |
| 100 lots | 50,000 | HK$ 840,000 |
| 120 lots | 60,000 | HK$ 1,008,000 |
| 140 lots | 70,000 | HK$ 1,176,000 |
| 160 lots | 80,000 | HK$ 1,344,000 |
| 180 lots | 90,000 | HK$ 1,512,000 |
| 200 lots | 100,000 | HK$ 1,680,000 |
| 300 lots | 150,000 | HK$ 2,520,000 |
| 400 lots | 200,000 | HK$ 3,360,000 |
| 500 lots | 250,000 | HK$ 4,200,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 300,000 | HK$ 5,040,000 |
| 700 lots | 350,000 | HK$ 5,880,000 |
| 800 lots | 400,000 | HK$ 6,720,000 |
| 900 lots | 450,000 | HK$ 7,560,000 |
| 1,000 lots | 500,000 | HK$ 8,400,000 |
| 1,200 lots | 600,000 | HK$ 10,080,000 |
| 1,400 lots | 700,000 | HK$ 11,760,000 |
| 1,600 lots | 800,000 | HK$ 13,440,000 |
| 1,800 lots | 900,000 | HK$ 15,120,000 |
| 2,000 lots | 1,000,000 | HK$ 16,800,000 |
| 4,000 lots | 2,000,000 | HK$ 33,600,000 |
| 6,000 lots | 3,000,000 | HK$ 50,400,000 |
| 8,000 lots | 4,000,000 | HK$ 67,200,000 |
| 10,000 lots | 5,000,000 | HK$ 84,000,000 |
| 10,486 lots | 5,243,350 | HK$ 88,088,280 |
| 12,357 lots | 6,178,500 | HK$ 103,798,800 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.46B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +543% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,990,612,400 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣727.0百萬元 |
| Period-End Cash Balance | 人民幣65.1百萬元 |
| Listing Expenses | ~HK$ 130,444,000 |
| Listing Expenses / Funds Raised | ~6.28% |
| Total Pre-IPO Investment | 人民幣1310.7百萬元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Profit for the year | -122,077 | -726,981 |
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 154,769 | 65,096 |
| Total current assets | 379,607 | 913,623 |
| Total assets | 554,214 | 1,226,586 |
| Total current liabilities | 183,834 | 53,666 |
| Total liabilities | 579,746 | 1,972,554 |
| Total equity | -25,532 | -745,968 |
| Interest-bearing borrowings | 0 | 10,000 |
Cash Flow Statement
| Item | 2019 | 2020 |
|---|---|---|
| Net cash from operating activities | -55,212 | -103,425 |
| Net cash from investing activities | -104,990 | -955,483 |
| Net cash from financing activities | 302,886 | 973,687 |
| Net increase in cash | 142,684 | -85,221 |
| Depreciation of PP&E | 14,525 | 17,787 |
| Amortisation of intangible assets | 2,044 | 2,066 |
| Purchase of PP&E | -18,622 | -25,294 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 14.32 |
|---|---|
| First Day Open | HK$ 15.52 |
| First Day Change | -14.76% |
| First Day Volume | 41422900.0 |
| First Day Turnover | 620468000.0 |
| Use of Proceeds | 1、約621.3百萬港元(占所得款項凈額的32.0%)將用于我們截至最后實際可行日期由25種候選藥物組成的龐大管線中兩種核心產品的臨床開發及商業化;
2、約893.1百萬港元(占所得款項凈額的46.0%)將用于為我們的其他在研候選藥物的持續研發活動及商業化提供資金;
3、約135.9百萬港元(占所得款項凈額的7.0%)將用于我們位于南沙的先進生產設施進行生產線擴張,以籌備未來年度的產品上市;
4、約97.1百萬港元(占所得款項凈額的5.0%)將用于為我們的業務開發活動及在研藥物的擴展提供資金;
5、約194.2百萬港元(占所得款項凈額的10.0%)將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (8)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | CaaS Capital Master Fund LP | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 2 | GIC Private Limited | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 3 | Golden Valley Global Limited | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 4 | Jennison Associates LLC | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 5 | Mass Ave Global, Inc. | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 6 | Matthews Asia Funds | 116,667,600 HKD | — | 5.62% | — | 6 months | 2021-10-29 |
| 7 | OrbiMed Funds | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 8 | VMS Zhaoke Investment Fund SP | 77,775,600 HKD | — | 3.75% | — | 6 months | 2021-10-29 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李小羿 | — |
| Company Secretary | 邱淑欣 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李氏大藥廠持有約26.2%權益,為單一最大股東;GIC Private Limited透過其受控法團持有13.3%;其他主要股東包括Panacea Venture Healthcare Fund I, L.P.(6.2%)、VMS Holdings Limited(5.8%)、COFL Holdings Limited(5.7%)及TPG Asia VII SF Pte. Ltd.(5.7%)等。 |
|---|




